1
|
Afari J, Spektor TM, Turner C, Cohen A, Bessudo A, Jhangiani H, Gabrail N, Kubba S, Neidhart JD, Eshaghian S, Swift RA, Eades BM, Kim C, Kim S, Vescio R, Berenson JR. Efficacy and safety of replacing lenalidomide with pomalidomide for patients with multiple myeloma refractory to a lenalidomide-containing combination regimen. Exp Hematol 2022; 114:54-60. [DOI: 10.1016/j.exphem.2022.07.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 07/21/2022] [Accepted: 07/29/2022] [Indexed: 11/04/2022]
|
2
|
Davar D, Singel SM, Nyamuswa G, Tran TA, Wu Y, Grewal J, Aghmesheh M, Spira A, Ganju V, Rand J, Frentzas S, Bajor D, Gabrail N. Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-ct252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Toll-like receptors (TLRs) play a key role in innate immune cell recognition of foreign pathogens, stimulating innate and adaptive immune responses. TLR agonists amplify tumor antigen-specific immune responses in the context of anti-PD-1 therapy. TransCon TLR7/8 Agonist is designed as a long-acting prodrug to provide localized delivery of resiquimod, a potent TLR7/8 agonist. TransCon TLR7/8 Agonist has the potential to improve on challenges of pattern recognition receptor agonist treatments by providing prolonged high local concentrations of resiquimod and promoting potent anti-tumoral responses while reducing systemic drug exposure and related adverse events. TransCon TLR7/8 Agonist comprises 3 main components: resiquimod, a polymeric hydrogel microparticle carrier, and a linker bound permanently to the hydrogel microparticle carrier on one end and transiently to resiquimod on the other. TLR-mediated T cell activation induces PD-1 expression on T cells, providing a clear rationale to study TransCon TLR7/8 Agonist alone and in combination with pembrolizumab (pembro). Intratumoral TransCon TLR7/8 Agonist is expected to stimulate innate and adaptive immune response in the tumor microenvironment and further enhance the activity of checkpoint inhibitors like pembro.
Methods: transcendIT-101 is a multicenter, first-in-human, Phase 1/2 study in 3 parts in adult patients with locally advanced, unresectable, recurrent, or metastatic solid tumors. All patients must have at least 2 measurable lesions by RECIST 1.1 that are predesignated as target-injected and target non-injected lesions, respectively. The primary objectives are to evaluate the safety, tolerability, define the maximum tolerated dose and recommended Phase 2 dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembro. Parts 1 and 2 Dose Escalation (Phase 1) use a standard 3+3 design with increasing doses of TransCon TLR7/8 Agonist alone (Part 1) or with 200 mg intravenous pembro in solid tumors where pembro monotherapy may have clinical activity (Part 2). Each part will enroll ≈20 patients. Part 3 Combination Dose Expansion (Phase 2) will evaluate preliminary clinical efficacy of TransCon TLR7/8 Agonist at the RP2D determined in Part 2 combined with pembro. Currently planned expansion cohorts are 1) head and neck squamous cell carcinoma, 2) other HPV-associated tumors (anal, vulvar, cervical, penile, vaginal). Each cohort will be analyzed using a Simon 2-stage design and will enroll ≈50 patients. Secondary objectives are TransCon TLR7/8 Agonist pharmacokinetics and its antitumor activity using ORR, duration of response, time to response by RECIST 1.1 and itRECIST; progression-free survival; overall survival. Recruitment started March 2021 and is ongoing (NCT04799054).
Citation Format: Diwakar Davar, Stina M. Singel, Gil Nyamuswa, Tuan-Anh Tran, Yang Wu, Jaspreet Grewal, Morteza Aghmesheh, Alexander Spira, Vinod Ganju, Jamie Rand, Sophia Frentzas, David Bajor, Nashat Gabrail. transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT252.
Collapse
Affiliation(s)
- Diwakar Davar
- 1University of Pittsburgh Medical Center, Pittsburgh, PA
| | | | | | | | - Yang Wu
- 2Ascendis Pharma, Palo Alto, CA
| | | | | | | | - Vinod Ganju
- 6Peninsula and Southeast Oncology, Franskton, Australia
| | | | | | - David Bajor
- 9University Hospitals Cleveland Medical Center, Cleveland, OH
| | | |
Collapse
|
3
|
Yap TA, Tan DS, Stathis A, Shapiro GI, Iwasa S, Joerger M, Zhang J, Plummer R, Sawyer M, Tan AC, Castonguay V, Gabrail N, Matsubara N, Wilkinson G, Ludwig M, Zhou Y, Merz C, Hreiki J, Sharma N, deBono J. Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-ct006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: ATR kinase is a critical component of DDR machinery and is activated by DNA damage or replication stress. Elimusertib is a selective ATR inhibitor with promising antitumor activity in pts with advanced solid tumors with ataxia telangiectasia mutated (ATM) protein loss and/or ATM putative deleterious alterations (Yap et al. Cancer Discov 2021). We report here the safety and efficacy of elimusertib in expansion cohorts of pts with a range of cancer types and DDR deficiencies and/or ATM loss. We also explored an alternative dose schedule in pts with ATM aberrations.
Methods: Pts with advanced solid tumors resistant or refractory to standard treatment were screened for pathogenic DDR defects by next-generation sequencing or ATM protein loss by immunohistochemistry (IHC) analysis of baseline tumor tissue. Pts were assigned to cohorts: colorectal cancer (CRC); castration-resistant prostate cancer (CRPC); HER2− breast cancer (BC); gynecologic (GYN, mainly ovarian and endometrial); and advanced cancers with ATM IHC loss. Pts were treated with elimusertib 40 mg twice daily (BID) 3 days on/4 days off (3 on/4 off). A schedule of 3 on/11 off was also explored by dose escalation in pts with ATM loss or inactivating mutation.
Results: 143 pts received ≥1 dose of elimusertib 40 mg BID 3 on/4 off, including 24 CRC, 19 CRPC, 19 BC, 45 GYN, and 36 ATM loss. 56% of pts had ≥4 prior therapy lines. Drug-related grade 3 and 4 treatment-emergent adverse events (TEAEs) were observed in 69% and 15% of pts, respectively, mainly anemia, leukopenia/neutropenia, and thrombocytopenia leading to dose modification but not withdrawal. 32 pts were treated 3 on/11 off with doses from 60 to 120 mg BID. Compared with 3 on/4 off, drug-related grade ≥3 hematologic TEAEs and dose modifications improved at lower doses, with 80 mg 3 on/11 off determined as the recommended dose. In pts receiving elimusertib 3 on/4 off, 5 RECIST partial responses were observed: 1 in ovarian (BRCA1 heterozygous mutation), 1 in BC (BRCA2 mutation), and 3 in ATM IHC loss: 2 CRPC pts both with ATM mutations (1 heterozygous, 1 homozygous), including 1 with FANCA mutation; 1 esophageal with ATM mutation. In pts with ATM IHC loss, objective response rate (ORR) was 9% and disease control rate (DCR) was 65%. A similar ORR was seen on 3 on/11 off in pts with ATM aberrations. In GYN pts, ORR was 2.3% and DCR was 73%.
Conclusions: Elimusertib monotherapy demonstrated clinical activity in pts with DDR defects. Overall safety was manageable and hematologic toxicity improved on the 3 on/11 off schedule. Further biomarker analysis is underway to identify potential gene signatures associated with response. Clinical development of elimusertib in combination with checkpoint inhibitors and chemotherapy is ongoing (NCT04095273, NCT04514497).
Citation Format: Timothy A. Yap, David S. Tan, Anastasios Stathis, Geoffrey I. Shapiro, Satoru Iwasa, Markus Joerger, Jingsong Zhang, Ruth Plummer, Michael Sawyer, Aaron C. Tan, Vincent Castonguay, Nashat Gabrail, Nobuaki Matsubara, Gary Wilkinson, Matthias Ludwig, Yinghui Zhou, Claudia Merz, Joseph Hreiki, Neelesh Sharma, Johan deBono. Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT006.
Collapse
Affiliation(s)
- Timothy A. Yap
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - David S. Tan
- 2National University Hospital, Singapore, Singapore
| | | | | | | | | | - Jingsong Zhang
- 7H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Ruth Plummer
- 8Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom
| | | | | | | | | | | | | | | | - Yinghui Zhou
- 16Bayer HealthCare Pharmaceuticals, Inc., Cambridge, MA
| | | | - Joseph Hreiki
- 14Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ
| | | | - Johan deBono
- 17Royal Marsden NHS Trust (Surrey), Sutton, United Kingdom
| |
Collapse
|
4
|
Qing Z, Gabrail N, Uprety D, Rotow J, Han B, Jänne P, Nagasaka M, Zheng M, Zhang Y, Yang G, Sun Y, Peng B, Wu YL. 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Yap TA, Bessudo A, Hamilton E, Sachdev J, Patel MR, Rodon J, Evilevitch L, Duncan M, Guo W, Kumar S, Lu S, Dezube BJ, Gabrail N. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer 2022; 10:jitc-2021-003924. [PMID: 35332062 PMCID: PMC8948406 DOI: 10.1136/jitc-2021-003924] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/03/2022] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and associated with improved antitumor activity. The objective of this trial was to determine the recommended phase 2 doses (RP2Ds) and to assess the safety and efficacy of the programmed cell death protein 1 (PD-1) inhibitor dostarlimab in combination with (1) the poly(ADP-ribose) polymerase inhibitor niraparib with or without vascular endothelial growth factor inhibitor bevacizumab or (2) carboplatin-paclitaxel chemotherapy with or without bevacizumab, in patients with advanced cancer. METHODS IOLite is a multicenter, open-label, multi-arm clinical trial. Patients with advanced solid tumors were enrolled. Patients received dostarlimab in combination with niraparib with or without bevacizumab or in combination with carboplatin-paclitaxel with or without bevacizumab until disease progression, unacceptable toxicity, or withdrawal from the study. Prespecified endpoints in all parts were to evaluate the dose-limiting toxicities (DLTs), RP2Ds, pharmacokinetics (PKs), and preliminary efficacy for each combination. RESULTS A total of 55 patients were enrolled; patients received dostarlimab and: (1) niraparib in part A (n=22); (2) carboplatin-paclitaxel in part B (n=14); (3) niraparib plus bevacizumab in part C (n=13); (4) carboplatin-paclitaxel plus bevacizumab in part D (n=6). The RP2Ds of all combinations were determined. All combinations were safe and tolerable, with no new safety signals observed. DLTs were reported in 2, 1, 2, and 0 patients, in parts A-D, respectively. Preliminary antitumor activity was observed, with confirmed Response Evaluation Criteria in Solid Tumors v1.1 complete/partial responses reported in 4 of 22 patients (18.2%), 6 of 14 patients (42.9%), 4 of 13 patients (30.8%), and 3 of 6 (50.0%) patients, in parts A-D, respectively. Disease control rates were 40.9%, 57.1%, 84.6%, and 83.3%, in parts A-D, respectively. Dostarlimab PK was unaffected by any combinations tested. Coadministration of bevacizumab showed no impact on niraparib PKs. The overall mean PD-1 receptor occupancy was 99.0%. CONCLUSIONS Dostarlimab was well tolerated in both doublet and triplet regimens tested, with promising antitumor activity observed with all combinations. We observed higher disease control rates in the triplet regimens than in doublet regimens. TRIAL REGISTRATION NUMBER NCT03307785.
Collapse
Affiliation(s)
- Timothy A Yap
- Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Alberto Bessudo
- California Cancer Associates for Research and Excellence, San Diego, California, USA
| | - Erika Hamilton
- Sara Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA
| | - Jasgit Sachdev
- HonorHealth Research Institute/TGen, Scottsdale, Arizona, USA
| | - Manish R Patel
- Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA
| | - Jordi Rodon
- Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | | | | | - Wei Guo
- GlaxoSmithKline, Waltham, Massachusetts, USA
| | | | - Sharon Lu
- GlaxoSmithKline, Waltham, Massachusetts, USA
| | | | - Nashat Gabrail
- Department of Oncology, Gabrail Cancer Center, Canton, Ohio, USA
| |
Collapse
|
6
|
Carneiro BA, Jotte R, Gabrail N, Hamid O, Huang F, Chaturvedi S, Herpers M, Soler LM, Childs BH, Hansen A. Abstract P239: Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors. Mol Cancer Ther 2021. [DOI: 10.1158/1535-7163.targ-21-p239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Copanlisib (C) is a pan-class I PI3K inhibitor, with predominant activity against the PI3K-α and -δ isoforms, approved for patients (pts) with relapsed follicular lymphoma. The PD-1 inhibitor nivolumab (N) is approved for several advanced or metastatic solid tumors. Following preclinical demonstration of the immunomodulatory activity of C (Glaeske et al. AACR 2018), we report Phase Ib results evaluating the safety and efficacy of C+N in pts with advanced solid tumors (NCT03735628). Methods: PD-1 inhibitor-naive adult pts with advanced solid tumors received C 45 mg or 60 mg i.v. (days 1, 8, and 15; 28-day cycle) and N 240 mg (day 15 of cycle 1 and days 1 and 15 of subsequent cycles). The primary objective was determination of the recommended Phase II dose (RP2D) of C in combination with N. Secondary endpoints were safety/tolerability, pharmacokinetics (PK), and efficacy. Exploratory real-time evaluation of 77 pharmacodynamic and predictive immune cell biomarkers by flow cytometry on whole blood was performed. Results: 16 pts were treated (C 45 mg + N 240 mg, n=5; C 60 mg + N 240 mg, n=11). Median age was 65 years (range 37–89), 12 pts (75%) were male, and 8 pts (50%) had stage IV disease at diagnosis; the most common tumor types were head and neck squamous cell carcinoma (HNSCC; 7 pts) and bladder cancer (BC; 4 pts). No dose-limiting toxicities were reported. The RP2D of C+N 240 mg was 60 mg. As of 13 May 2020, 4 pts remain on treatment. The most common treatment-emergent adverse events (TEAEs) of any grade were hypertension and diarrhea (7 pts [44%] each, ≤ grade [G] 3) and maculo-papular rash and fatigue (6 pts [38%] each, ≤G3). C-related TEAEs were reported in 88% of pts, all ≤G3. AEs leading to C dose interruption/reduction were reported in 31%/19% of pts; TEAEs led to C discontinuation in 1 pt (60 mg; hematuria). Serious AEs occurred in 5 pts (31%). One G5 TEAE occurred (45 mg; general physical health deterioration, unrelated to C or N). No PK interactions were observed between C and N. Two pts had a partial response: 1 in the C 45 mg group (HNSCC) and 1 in the 60 mg group (BC; benefit sustained after 19 cycles). Stable disease was seen in 10 pts and disease progression in 3 pts; disease control rate (DCR) was 75%. Maximum decrease in circulating monocytic myeloid-derived suppressor cells (M-MDSCs; p<0.05) from baseline occurred on day 2 after C, returning to baseline on day 8. A significant increase in activated (HLA-DR+ and CD38+) natural killer and CD8+ T cells was seen 2 weeks post-treatment with C+N. Lower baseline levels of CD8+ Teffector memory (TEM) subset CD45RA-/CCR7- (CD3+/CD8+) seemed to associate with higher DCR. Conclusions: C+N showed acceptable safety and preliminary efficacy in pts with advanced solid tumors. The immunomodulatory effect of C on M-MDSCs was seen 2 days post-treatment, and lower TEM subset levels seemed to associate with better disease control. These results support further investigation of C+N in pts with advanced solid tumors. Funding: Bayer AG. Writing support: Complete HealthVizion.
Citation Format: Benedito A. Carneiro, Robert Jotte, Nashat Gabrail, Omid Hamid, Funan Huang, Shalini Chaturvedi, Matthias Herpers, Lidia Mongay Soler, Barrett H. Childs, Aaron Hansen. Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P239.
Collapse
Affiliation(s)
| | | | | | - Omid Hamid
- 4The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA,
| | - Funan Huang
- 5Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ,
| | | | | | | | | | - Aaron Hansen
- 7Princess Margaret Cancer Centre, Toronto, Canada
| |
Collapse
|
7
|
Savona M, Mccloskey J, Griffiths E, Yee K, Al-Kali A, Zeidan A, Deeg H, Patel P, Sabloff M, Keating MM, Dao KH, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, Dezern A, O’Connell C, Roboz G, Busque L, Wells R, Amin H, Randhawa J, Leber B, Hao Y, Keer H, Azab M, Manero GG. Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106681.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Arkenau HT, Guthrie T, Mekhail T, Cortinovis D, Antonuzzo L, Bruce J, Gabrail N, Anderson I, Oh S, Oh S, Nott L, Shah M, Sanborn R, Oh DY, Cho J, Lin CC, Lee A, Wang Y, Wang Z, Sher A. 643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
9
|
Haymaker C, Johnson DH, Murthy R, Bentebibel SE, Uemura MI, Hudgens CW, Safa H, James M, Andtbacka RHI, Johnson DB, Shaheen M, Davies MA, Rahimian S, Chunduru SK, Milton DR, Tetzlaff MT, Overwijk WW, Hwu P, Gabrail N, Agrawal S, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov 2021; 11:1996-2013. [PMID: 33707233 PMCID: PMC8544022 DOI: 10.1158/2159-8290.cd-20-1546] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 02/08/2021] [Accepted: 03/09/2021] [Indexed: 11/16/2022]
Abstract
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients with anti-PD-1- resistant advanced melanoma. In all patients, 48.4% experienced grade 3/4 treatment-emergent adverse events. The overall response rate at the recommended phase II dose of 8 mg was 22.4%, and an additional 49% of patients had stable disease. Responses in noninjected lesions and in patients expected to be resistant to ipilimumab monotherapy were observed. Rapid induction of a local IFNα gene signature, dendritic cell maturation and enhanced markers of antigen presentation, and T-cell clonal expansion correlated with clinical response. A phase III clinical trial with this combination (NCT03445533) is ongoing. SIGNIFICANCE: Despite recent developments in advanced melanoma therapies, most patients do not experience durable responses. Intratumoral tilsotolimod injection elicits a rapid, local type 1 IFN response and, in combination with ipilimumab, activates T cells to promote clinical activity, including in distant lesions and patients not expected to respond to ipilimumab alone.This article is highlighted in the In This Issue feature, p. 1861.
Collapse
Affiliation(s)
- Cara Haymaker
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Daniel H Johnson
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Ravi Murthy
- Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Salah-Eddine Bentebibel
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Marc I Uemura
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Courtney W Hudgens
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Houssein Safa
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Marihella James
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Robert H I Andtbacka
- Surgical Oncology Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Douglas B Johnson
- Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Montaser Shaheen
- Department of Medicine and Cancer Center, University of Arizona, Tucson, Arizona
| | - Michael A Davies
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | | | - Denái R Milton
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Michael T Tetzlaff
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Willem W Overwijk
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Patrick Hwu
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Nashat Gabrail
- Department of Oncology, Gabrail Cancer Center, Canton, Ohio
| | - Sudhir Agrawal
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts
| | - Gary Doolittle
- Department of Oncology, University of Kansas Medical Center, Kansas City, Kansas
| | - Igor Puzanov
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York
| | - Joseph Markowitz
- Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
| | - Chantale Bernatchez
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
| | - Adi Diab
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
| |
Collapse
|
10
|
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J 2021; 11:89. [PMID: 33980831 PMCID: PMC8116334 DOI: 10.1038/s41408-021-00478-4] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 03/11/2021] [Accepted: 04/15/2021] [Indexed: 11/09/2022] Open
Affiliation(s)
- Joseph Mikhael
- Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA
| | | | - Cyrille Hulin
- Service d'hématologie, CHRU Hôpitaux de Brabois, Nancy, France
| | - Laure Vincent
- Département d'hématologie Clinique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Philippe Moreau
- Hematology Department, Nantes University Hospital, Nantes, France
| | | | - Ludek Pour
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
| | - Ivan Spicka
- 1st Department of Medicine-Department of Hematology First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic
| | - Ravi Vij
- Division of Medical Oncology, Washington University, St Louis, MO, USA
| | - Jeffrey Zonder
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
| | - Djordje Atanackovic
- Department of Medicine, Bone Marrow Transplant, University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
| | | | - Thomas G Martin
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Aurore Perrot
- CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'hématologie, Toulouse, France
| | | | - Qilong Weng
- Sanofi Clinical Sciences and Operations, Beijing, China
| | - Claire Brillac
- Sanofi Translational Medicine and Early Development, Paris, France
| | - Dorothée Semiond
- Sanofi Translational Medicine and Early Development, Paris, France
| | - Sandrine Macé
- Sanofi Translational Medicine and Early Development, Paris, France
| | - Kathryn P Corzo
- Sanofi Global Oncology, Cambridge, MA, USA.,CHU and CIC Inserm1402, Poitiers, France
| | | |
Collapse
|
11
|
Sanborn R, Hauke R, Gabrail N, O’Hara M, Bhardwaj N, Bordoni R, Gordon M, Khalil D, Abdelrahim M, Marron T, Hawthorne T, Thomas L, Rawls T, Rogalski M, Alvarado D, Vitale L, Keler T, Yellin M. 405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3). J Immunother Cancer 2020. [DOI: 10.1136/jitc-2020-sitc2020.0405] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
BackgroundCDX-1140 is an agonist anti-CD40 mAb selected to optimize systemic exposure and hence tumor microenvironment (TME) ingress. CDX-1140 activity may be enhanced by combining with CDX-301 (recombinant Flt3L), a dendritic cell growth factor, or with pembrolizumab, an anti-PD-1 mAb.MethodsPatients with advanced solid or hematologic (Part 1 only) tumors are enrolled. Part 1 dose-escalation results have been presented (SITC 2019). In Part 2, CDX-1140 dose-escalation (0.09–1.5 mg/kg q4w) is in combination with CDX-301 (75 mcg/kg sc QD x 5 for 2 cycles). In Part 3, CDX-1140 dose-escalation (0.72–1.5 mg/kg q3w) is in combination with pembrolizumab 200 mg q3w. Part 1 and 2 expansion cohorts are dosed at the CDX-1140 MTD, 1.5 mg/kg q4w. Part 3 expansion cohorts are planned. Peripheral blood and tumor biomarkers analysis are ongoing.Results92 patients have been treated (Part 1 n=57, Part 2 n=31, Part 3 n=4). Part 1 expansion cohorts in SCCHN (n=7) and RCC (n=5) are fully enrolled. Part 2 dose-escalation completed to the highest CDX-1140 dose and a SCCHN expansion cohort is ongoing. Part 3 dose-escalation recently initiated. Safety data is available for 23 and 10 patients at the MTD in Part 1 and 2, respectively. In general, the safety profiles were similar, with arthralgia (52% vs. 50%), pyrexia (44% vs 50%), fatigue (30% vs. 50%), chills (39% vs. 40%), vomiting (30% vs. 20%), nausea (26% vs 40%), myalgia (22% vs. 30%), increased ALT (22% vs. 20%), and increased AST (22% vs. 30%) being the most common drug related AEs at the MTD in Part 1 and 2, respectively. Most AEs were low grade. Across all cohorts, cytokine release syndrome (CRS) (G2 n=4, G3 n=2) occurred in 6 (Part 1 n=2; Part 2 n=4) and pneumonitis (G3) occurred in 5 (Part 1 n=4; Part 2 n=1) patients. Immune activation in the TME consistent with CD40 agonism and increases serum inflammatory cytokines were observed. Evidence of anti-tumor activity/clinical benefit include SD (n=13), tumor cavitation (n=2) and a uPR in solid tumors. A patient with follicular lymphoma has an ongoing durable complete metabolic response.ConclusionsThe CDX-1140 MTD dose of 1.5 mg/kg, a dose level expected to provide good systemic exposure and TME penetration, is generally well tolerated alone and with CDX-301. Transaminitis and CRS have generally been low grade and infrequent. A cohort combining CDX-1140 with chemotherapy will be initiated in patients with previously untreated metastatic pancreatic adenocarcinoma.Trial RegistrationNCT03329950Ethics ApprovalThe study was approved by the following: Providence St. Joseph Health IRB, approval number MOD2020001128; WIRB, approval number 1188814 (Hauke, Gabrail, Bordoni & Gordon); University of Pennsylvania IRB, approval number UPCC 18917; Mount Sinai School of Medicine IRB, approval number 18-00202; Memorial Sloan Kettering Cancer Center IRB, approval number 18-225A; Houston Methodist IRB, approval number MOD00000836
Collapse
|
12
|
Haymaker C, Andtbacka R, Johnson D, Shaheen M, Rahimian S, Chunduru S, Gabrail N, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1207] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Vogelzang N, Gabrail N, Malik Z, Volterra F, Nordquist L, Levin R, Zhang P, Zhou K. The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VTD, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol 2018; 37:nbt.4313. [PMID: 30556813 DOI: 10.1038/nbt.4313] [Citation(s) in RCA: 151] [Impact Index Per Article: 25.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 11/06/2018] [Indexed: 12/30/2022]
Abstract
Neoantigens, which are expressed on tumor cells, are one of the main targets of an effective antitumor T-cell response. Cancer immunotherapies to target neoantigens are of growing interest and are in early human trials, but methods to identify neoantigens either require invasive or difficult-to-obtain clinical specimens, require the screening of hundreds to thousands of synthetic peptides or tandem minigenes, or are only relevant to specific human leukocyte antigen (HLA) alleles. We apply deep learning to a large (N = 74 patients) HLA peptide and genomic dataset from various human tumors to create a computational model of antigen presentation for neoantigen prediction. We show that our model, named EDGE, increases the positive predictive value of HLA antigen prediction by up to ninefold. We apply EDGE to enable identification of neoantigens and neoantigen-reactive T cells using routine clinical specimens and small numbers of synthetic peptides for most common HLA alleles. EDGE could enable an improved ability to develop neoantigen-targeted immunotherapies for cancer patients.
Collapse
Affiliation(s)
| | - Jennifer Busby
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Christine D Palmer
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Matthew J Davis
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Tyler Murphy
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Andrew Clark
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Michele Busby
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Fujiko Duke
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Aaron Yang
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Lauren Young
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Noelle C Ojo
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Kamilah Caldwell
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Jesse Abhyankar
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Thomas Boucher
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Meghan G Hart
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | | | | | - Olaf Mercier
- Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France
| | - Timothy A Chan
- Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Giorgio Scagliotti
- University of Turin, Department of Oncology at San Luigi Hospital, Orbassano (Turin), Italy
| | - Paolo Bironzo
- University of Turin, Department of Oncology at San Luigi Hospital, Orbassano (Turin), Italy
| | - Silvia Novello
- University of Turin, Department of Oncology at San Luigi Hospital, Orbassano (Turin), Italy
| | - Niki Karachaliou
- Instituto Oncologico Dr. Rosell - Hospital Universitari Quiron Dexeus Location, Barcelona, Spain
| | | | - Ian Anderson
- St Joseph Heritage Healthcare, Santa Rosa, California, USA
| | | | - John Hrom
- Hattiesburg Clinic/Forrest General Cancer Center, Hattiesburg, Mississippi, USA
| | | | | | | | - Raphael Rousseau
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Cynthia Voong
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Naiyer A Rizvi
- New York Presbyterian/Columbia University Medical Center, New York, New York, USA
| | - Elie Fadel
- Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France
| | - Mark Frattini
- New York Presbyterian/Columbia University Medical Center, New York, New York, USA
| | - Karin Jooss
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Mojca Skoberne
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Joshua Francis
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| | - Roman Yelensky
- Gritstone Oncology, Inc., Emeryville, California and Cambridge, Massachusetts, USA
| |
Collapse
|
15
|
Garon E, Wong D, Schneider J, Aljumaily R, Korn W, Patel M, Autio K, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Hung A, Oft M, Leveque J, Spigel D. Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Baumgart M, Muhsin M, Wu W, Gabrail N. HALO 107-201: A phase Ib, open-label, multicenter study of pegvorhyaluronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA. Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Res Treat 2018; 171:111-120. [PMID: 29744674 DOI: 10.1007/s10549-018-4813-z] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Accepted: 05/03/2018] [Indexed: 12/27/2022]
Abstract
PURPOSE Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK), and activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or ER+ breast cancer. METHODS Seviteronel was administered in de-escalating 750, 600, and 450 mg QD 6-subject cohorts. The 750 mg QD start dose was a phase 2 dose determined for men with castration-resistant prostate cancer in (Shore et al. J Clin Oncol 34, 2016). Enrollment at lower doses was initiated in the presence of dose-limiting toxicities (DLTs). The primary objective of this study was to determine seviteronel safety, tolerability, and MTD. The secondary objectives included description of its PK in women and its initial activity, including clinical benefit rate at 4 (CBR16) and 6 months (CBR24). RESULTS Nineteen women were enrolled. A majority of adverse events (AEs) were Grade (Gr) 1/2, independent of relationship; the most common were tremor (42%), nausea (42%), vomiting (37%), and fatigue (37%). Four Gr 3/4 AEs (anemia, delirium, mental status change, and confusional state) deemed possibly related to seviteronel occurred in four subjects. DLTs were observed at 750 mg (Gr 3 confusional state with paranoia) and 600 mg (Gr 3 mental status change and Gr 3 delirium) QD, with none at 450 mg QD. The recommended phase 2 dose (RP2D) was 450 mg QD, and at the RP2D, 4 of 7 subjects reached at least CBR16 (2 TNBC subjects and 2 ER+ subjects achieved CBR16 and CBR24, respectively); no objective tumor responses were reported. CONCLUSIONS Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D.
Collapse
Affiliation(s)
- Aditya Bardia
- Division of Hematology and Oncology, Breast Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114-2696, USA.
| | - Ayca Gucalp
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Noashir DaCosta
- North Shore Hematology Oncology Associates, East Setauket, NY, USA
| | | | | | | | | | - Lisa A Carey
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
| | | | | | - Tiffany A Traina
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
18
|
Wong D, Schneider J, Aljumaily R, Korn M, Autio K, Infante J, Patel M, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Van Vlasselaer P, Hung A, Brown G, Oft M, Garon E. Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Silk AW, Kaufman H, Gabrail N, Mehnert J, Bryan J, Norrell J, Medina D, Bommareddy P, Shafren D, Grose M, Zloza A. Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemicpembrolizumab inadvanced melanoma patients: Interim results of the CAPRA clinical trial. Clin Trials 2017. [DOI: 10.1158/1538-7445.am2017-ct026] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer Manag Res 2017; 9:179-187. [PMID: 28579832 PMCID: PMC5446958 DOI: 10.2147/cmar.s129059] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy (HEC) in the double-blind Phase III Modified Absorption of Granisetron In the prevention of CINV (MAGIC) trial. PATIENTS AND METHODS This MAGIC post hoc analysis evaluated CINV prevention efficacy and safety of APF530 versus ondansetron, each with fosaprepitant and dexamethasone, in patient subgroup receiving an anthracycline plus cyclophosphamide (AC) regimen. Patients were randomized 1:1 to APF530 500 mg subcutaneously (granisetron 10 mg) or ondansetron 0.15 mg/kg intravenously (IV) (≤16 mg); stratification was by planned cisplatin ≥50 mg/m2 (yes/no). Patients were to receive fosaprepitant 150 mg IV and dexamethasone 12 mg IV on day 1, then dexamethasone 8 mg orally once daily on day 2 and twice daily on days 3 and 4. Patients were mostly younger females (APF530 arm, mean age 54.1 years, female, 99.3%; ondansetron arm, 53.8 years, female 98.3%). The primary end point was delayed-phase (>24-120 hours) complete response (CR). RESULTS APF530 versus ondansetron regimens achieved numerically better CINV control in delayed and overall (0-120 hours) phases for CR, complete control, total response, rescue medication use, and proportion with no nausea. APF530 trends are consistent with the overall population, although not statistically superior given the underpowered AC subgroup analysis. The APF530 regimen in this population was generally well tolerated, with safety comparable to that of the overall population. CONCLUSION APF530 plus fosaprepitant and dexamethasone effectively prevented CINV among patients receiving AC-based HEC, a large subgroup in whom CINV control has traditionally been challenging.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Sharon Wilks
- Cancer Care Centers of South Texas, San Antonio, TX
| | | | - Michael C Mosier
- Biostatistics, EMB Statistical Solutions, LLC, Overland Park, KS
| | | | | | | |
Collapse
|
21
|
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, Arnoux T, Chanuc F, Fuseri N, Wilkinson RW, Wagtmann N, Morel Y, Andre P, Atkins MB, Carlino MS, Ribas A, Thompson JA, Choueiri TK, Hodi FS, Hwu WJ, McDermott DF, Atkinson V, Cebon JS, Fitzharris B, Jameson MB, McNeil C, Hill AG, Mangin E, Ahamadi M, van Vugt M, van Zutphen M, Ibrahim N, Long GV, Gartrell R, Blake Z, Simoes I, Fu Y, Saito T, Qian Y, Lu Y, Saenger YM, Budhu S, De Henau O, Zappasodi R, Schlunegger K, Freimark B, Hutchins J, Barker CA, Wolchok JD, Merghoub T, Burova E, Allbritton O, Hong P, Dai J, Pei J, Liu M, Kantrowitz J, Lai V, Poueymirou W, MacDonald D, Ioffe E, Mohrs M, Olson W, Thurston G, Capasso C, Frascaro F, Carpi S, Tähtinen S, Feola S, Fusciello M, Peltonen K, Martins B, Sjöberg M, Pesonen S, Ranki T, Kyruk L, Ylösmäki E, Cerullo V, Cerignoli F, Xi B, Guenther G, Yu N, Muir L, Zhao L, Abassi Y, Cervera-Carrascón V, Siurala M, Santos J, Havunen R, Parviainen S, Hemminki A, Alemany R, Loskog A, Jhawar S, Goyal S, Bommareddy PK, Paneque T, Kaufman HL, Zloza A, Kaufman HL, Silk A, Dalgleish A, Mehnert J, Gabrail N, Bryan J, Medina D, Bommareddy PK, Shafren D, Grose M, Zloza A, Mitchell L, Yagiz K, Mudan S, Lopez F, Mendoza D, Munday A, Gruber H, Jolly D, Fuhrmann S, Radoja S, Tan W, Pourchet A, Frey A, DeBenedette M, Mohr I, Mulvey M, Ranki T, Pesonen S, Capasso C, Ylösmäki E, Cerullo V, Andtbacka RHI, Ross M, Agarwala S, Plachco A, Grossmann K, Taylor M, Vetto J, Neves R, Daud A, Khong H, Meek SM, Ungerleider R, Welden S, Tanaka M, Gamble A, Williams M, Andtbacka RHI, Curti B, Hallmeyer S, Fox B, Feng Z, Paustian C, Bifulco C, Grose M, Shafren D, Grogan EW, Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tähtinen S, Bramante S, Vassilev L, Wang H, Lieber A, Krisko J, Hemmi S, de Gruijl T, Kanerva A, Hemminki A, Ansari T, Sundararaman S, Roen D, Lehmann P, Bloom AC, Bender LH, Tcherepanova I, Walters IB, Terabe M, Berzofsky JA, Chapelin F, Okada H, Ahrens ET, DeFalco J, Harbell M, Manning-Bog A, Scholz A, Nicolette C, Zhang D, Baia G, Tan YC, Sokolove J, Kim D, Williamson K, Chen X, Colrain J, Santo GE, Nguyen N, Dhupkar P, Volkmuth W, Greenberg N, Robinson W, Emerling D, Drake CG, Petrylak DP, Antonarakis ES, Kibel AS, Chang NN, Vu T, Yu L, Campogan D, Haynes H, Trager JB, Sheikh NA, Quinn DI, Kirk P, Addepalli M, Chang T, Zhang P, Konakova M, Kleinerman ES, Hagihara K, Pai S, VanderVeen L, Obalapur P, Kuo P, Quach P, Fong L, Charych DH, Zalevsky J, Langowski JL, Gordon N, Addepalli M, Kirksey Y, Nutakki R, Kolarkar S, Pena R, Hoch U, Zalevsky J, Doberstein SK, Charych DH, Cha J, Grenga I, Mallon Z, Perez M, McDaniel A, Anand S, Uecker D, Nuccitelli R, McDaniel A, Anand S, Cha J, Uecker D, Lepone L, Nuccitelli R, Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett D, Kalinski P, Renrick AN, Thounaojam M, Gameiro S, Thomas P, Pellom S, Shanker A, Pellom S, Thounaojam M, Dudimah D, Brooks A, Sayers TJ, Shanker A, Su YL, Knudson KM, Adamus T, Zhang Q, Nechaev S, Kortylewski M, Wei S, Allison J, Anderson C, Tang C, Schoenhals J, Tsouko E, Fantini M, Heymach J, de Groot P, Chang J, Hess KR, Diab A, Sharma P, Allison J, Naing A, Hong D, Welsh J, Tsang K, Albershardt TC, Parsons AJ, Leleux J, Reeves RS, ter Meulen J, Berglund P, Ascarateil S, Koziol ME, Penny SA, Malaker SA, Hodge J, Steadman L, Myers PT, Bai D, Shabanowitz J, Hunt DF, Cobbold M, Dai P, Wang W, Yang N, Shuman S, Donahue R, Merghoub T, Wolchok JD, Deng L, Dillon P, Petroni G, Brenin D, Bullock K, Olson W, Smolkin ME, Smith K, Schlom J, Nail C, Slingluff CL, Sharma M, Fa’ak F, Janssen L, Khong H, Xiao Z, Hailemichael Y, Singh M, Vianden C, Evans E, Diab A, Zalevsky J, Hoch U, Overwijk WW, Facciabene A, Stefano P, Chongyung F, Rafail S, Hailemichael Y, Nielsen M, Bussler H, Fa’ak F, Vanderslice P, Woodside DG, Market RV, Biediger RJ, Marathi UK, Overwijk WW, Hollevoet K, Geukens N, Declerck P, Mallow C, Joly N, McIntosh L, Paramithiotis E, Rizell M, Sternby M, Andersson B, Karlsson-Parra A, Kuai R, Ochyl L, Schwendeman A, Reilly C, Moon J, Deng W, Hudson TE, Lemmens EE, Hanson B, Rae CS, Burrill J, Skoble J, Katibah G, Murphy AL, Torno S, deVries M, Brockstedt DG, Leong ML, Lauer P, Dubensky TW, Whiting CC, Chen X, Hu Y, Xia Y, Zhou L, Scrivens M, Bao Y, Huang S, Ren X, Hurt E, Hollingsworth RE, Chang AE, Wicha MS, Li Q, Aggarwal C, Mangrolia D, Foster C, Cohen R, Weinstein G, Morrow M, Bauml J, Kraynyak K, Boyer J, Yan J, Lee J, Humeau L, Oyola S, Howell A, Duff S, Weiner D, Yang Z, Bagarazzi M, McNeel DG, Eickhoff J, Jeraj R, Staab MJ, Straus J, Rekoske B, Balch L, Liu G, Melssen M, Petroni G, Grosh W, Varhegyi N, Bullock K, Smolkin ME, Smith K, Galeassi N, Deacon DH, Knapp A, Gaughan E, Slingluff CL, Ghisoli M, Barve M, Mennel R, Wallraven G, Manning L, Senzer N, Nemunaitis J, Ogasawara M, Leonard JE, Ota S, Peace KM, Hale DF, Vreeland TJ, Jackson DO, Berry JS, Trappey AF, Herbert GS, Clifton GT, Hardin MO, Paris M, Toms A, Qiao N, Litton J, Peoples GE, Mittendorf EA, Ghamsari L, Flano E, Jacques J, Liu B, Havel J, Fisher T, Makarov V, Merghoub T, Wolchok JD, Hellmann MD, Chan TA, Flechtner JB, Stefano P, Facciabene A, Facciponte J, Ugel S, Hu-Lieskovan S, De Sanctis F, Coukos G, Paris S, Pottier A, Levy L, Lu B, Cappuccini F, Pollock E, Bryant R, Hamdy F, Ribas A, Hill A, Redchenko I, Sultan H, Kumai T, Fesenkova V, Celis E, Tsang K, Fantini M, Fernando I, Palena C, Smith E, David JM, Hodge J, Gabitzsch E, Jones F, Gulley JL, Schlom J, Herranz MU, Rafail S, Ugel S, Facciponte J, Zauderer M, Stefano P, Facciabene A, Wada H, Shimizu A, Osada T, Fukaya S, Sasaki E, Abolhalaj M, Askmyr D, Lundberg K, Fogler W, Albrekt AS, Greiff L, Lindstedt M, Flies DB, Higuchi T, Ornatowski W, Harris J, Adams SF, Aguilera T, Rafat M, Franklin M, Castellini L, Shehade H, Kariolis M, Jang D, vonEbyen R, Graves E, Ellies L, Rankin E, Koong A, Giaccia A, Thayer M, Ajina R, Wang S, Smith J, Pierobon M, Jablonski S, Petricoin E, Weiner LM, Sherry L, Waller J, Anderson M, Saims D, Bigley A, Bernatchez C, Haymaker C, Tannir NM, Kluger H, Tetzlaff M, Jackson N, Gergel I, Tagliaferri M, Zalevsky J, Magnani JL, Hoch U, Hwu P, Snzol M, Hurwitz M, Diab A, Barberi T, Martin A, Suresh R, Barakat D, Harris-Bookman S, Gong J, Drake C, Friedman A, Berkey S, Downs-Canner S, Delgoffe GM, Edwards RP, Curiel T, Odunsi K, Bartlett D, Obermajer N, Gray M, Bruno TC, Moore B, Squalls O, Ebner P, Waugh K, Mitchell J, Franklin W, Merrick D, McCarter M, Palmer B, Hutchins J, Kern J, Vignali D, Slansky J, Chan ASH, Qiu X, Fraser K, Jonas A, Ottoson N, Gordon K, Kangas TO, Freimark B, Leonardo S, Ertelt K, Walsh R, Uhlik M, Graff J, Bose N, Gupta R, Mandloi N, Paul K, Patil A, Fromm G, Sathian R, Mohan A, Manoharan M, Chaudhuri A, Chen Y, Lin J, Ye YB, Xu CW, Chen G, Guo ZQ, de Silva S, Komarov A, Chenchik A, Makhanov M, Frangou C, Zheng Y, Coltharp C, Unfricht D, Dilworth R, Fridman L, Liu L, Giffin L, Rajopadhye M, Miller P, Concha-Benavente F, Bauman J, Trivedi S, Srivastava R, Ohr J, Heron D, Duvvuri U, Kim S, Xu X, Gooding W, Ferris RL, Torrey H, Mera T, Okubo Y, Vanamee E, Foster R, Faustman D, Gartrell R, Stack E, Rose J, Lu Y, Izaki D, Beck K, Jia DT, Armenta P, White-Stern A, Fu Y, Blake Z, Marks D, Kaufman HL, Schreiber TH, Taback B, Horst B, Saenger YM, Glickman LH, Kanne DB, Gauthier KS, Desbien AL, Francica B, Katibah G, Corrales LP, Fantini M, Leong JL, Sung L, Metchette K, Kasibhatla S, Pferdekamper AM, Zheng L, Cho C, Feng Y, McKenna JM, Tallarico J, Gameiro SR, Bender S, Ndubaku C, McWhirter SM, Drake CG, Gajewski TF, Dubensky TW, Gugel EG, Bell CJM, Munk A, Muniz L, Knudson KM, Bhardwaj N, Zhao F, Evans K, Xiao C, Holtzhausen A, Hanks BA, Scholler N, Yin C, Van der Meijs P, Prantner AM, Clavijo PE, Krejsa CM, Smith L, Johnson B, Branstetter D, Stein PL, Jaen JC, Tan JBL, Chen A, Chen Y, Park T, Allen CT, Powers JP, Sexton H, Xu G, Young SW, Schindler U, Deng W, Klinke DJ, Komar HM, Mace T, Serpa G, Donahue R, Elnaggar O, Conwell D, Hart P, Schmidt C, Dillhoff M, Jin M, Ostrowski MC, Lesinski GB, Koti M, Au K, Lepone L, Peterson N, Truesdell P, Reid-Schachter G, Graham C, Craig A, Francis JA, Kotlan B, Balatoni T, Farkas E, Toth L, Grenga I, Ujhelyi M, Savolt A, Doleschall Z, Horvath S, Eles K, Olasz J, Csuka O, Kasler M, Liszkay G, Barnea E, Hodge JW, Kumar S, Tsujikawa T, Blakely C, Flynn P, Goodman R, Bueno R, Sugarbaker D, Jablons D, Broaddus VC, West B, Tsang KY, Coussens LM, Kunk PR, Obeid JM, Winters K, Pramoonjago P, Smolkin ME, Stelow EB, Bauer TW, Slingluff CL, Rahma OE, Schlom J, Lamble A, Kosaka Y, Huang F, Saser KA, Adams H, Tognon CE, Laderas T, McWeeney S, Loriaux M, Tyner JW, Gray M, Druker BJ, Lind EF, Liu Z, Lu S, Kane LP, Ferris RL, Liu Z, Shayan G, Lu S, Ferris RL, Gong J, Femel J, Tsujikawa T, Lane R, Booth J, Lund AW, Melssen M, Rodriguez A, Slingluff CL, Engelhard VH, Metelli A, Hutchins J, Wu BX, Fugle CW, Saleh R, Sun S, Wu J, Liu B, Li Z, Morris ZS, Guy EI, Heinze C, Freimark B, Kler J, Gressett MM, Werner LR, Gillies SD, Korman AJ, Loibner H, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM, Grogan J, Newman J, Zloza A, Huelsmann E, Broucek J, Kaufman HL, Brech D, Straub T, Irmler M, Beckers J, Buettner F, Manieri N, Schaeffeler E, Schwab M, Noessner E, Anand S, McDaniel A, Cha J, Uecker D, Nuccitelli R, Ordentlich P, Wolfreys A, Chiang E, Da Costa A, Silva J, Crosby A, Staelens L, Craggs G, Cauvin A, Mason S, Paterson AM, Lake AC, Armet CM, Caplazi P, O’Connor RW, Hill JA, Normant E, Adam A, Biniszkiewicz DM, Chappel SC, Palombella VJ, Holland PM, Powers JP, Becker A, Yadav M, Chen A, Leleti MR, Newcomb E, Sexton H, Schindler U, Tan JBL, Young SW, Jaen JC, Rapisuwon S, Radfar A, Hagner P, Gardner K, Gibney G, Atkins M, Rennier KR, Crowder R, Wang P, Pachynski RK, Carrero RMS, Rivas S, Beceren-Braun F, Chiu H, Anthony S, Schluns KS, Sawant D, Chikina M, Yano H, Workman C, Vignali D, Salerno E, Bedognetti D, Mauldin I, Waldman M, Deacon D, Shea S, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski T, Marincola FM, Slingluff CL, Spranger S, Klippel A, Horton B, Gajewski TF, Suzuki A, Leland P, Joshi BH, Puri RK, Sweis RF, Bao R, Luke J, Gajewski TF, Thakurta A, Theodoraki MN, Mogundo FM, Edwards RP, Kalinski P, Won H, Moreira D, Gao C, Zhao X, Duttagupta P, Jones J, Pourdehnad M, D’Apuzzo M, Pal S, Kortylewski M, Gandhi A, Henrich I, Quick L, Young R, Chou M, Hotson A, Willingham S, Ho P, Choy C, Laport G, McCaffery I, Miller R, Tipton KA, Wong KR, Singson V, Wong C, Chan C, Huang Y, Liu S, Richardson JH, Kavanaugh WM, West J, Irving BA, Tipton KA, Wong KR, Singson V, Wong C, Chan C, Huang Y, Liu S, Richardson JH, Kavanaugh WM, West J, Irving BA, Jaini R, Loya M, Eng C, Johnson ML, Adjei AA, Opyrchal M, Ramalingam S, Janne PA, Dominguez G, Gabrilovich D, de Leon L, Hasapidis J, Diede SJ, Ordentlich P, Cruickshank S, Meyers ML, Hellmann MD, Kalinski P, Zureikat A, Edwards R, Muthuswamy R, Obermajer N, Urban J, Butterfield LH, Gooding W, Zeh H, Bartlett D, Zubkova O, Agapova L, Kapralova M, Krasovskaia L, Ovsepyan A, Lykov M, Eremeev A, Bokovanov V, Grigoryeva O, Karpov A, Ruchko S, Nicolette C, Shuster A, Khalil DN, Campesato LF, Li Y, Merghoub T, Wolchok JD, Lazorchak AS, Patterson TD, Ding Y, Sasikumar P, Sudarshan N, Gowda N, Ramachandra R, Samiulla D, Giri S, Eswarappa R, Ramachandra M, Tuck D, Wyant T, Leshem J, Liu XF, Bera T, Terabe M, Bossenmaier B, Niederfellner G, Reiter Y, Pastan I, Xia L, Xia Y, Hu Y, Wang Y, Bao Y, Dai F, Huang S, Hurt E, Hollingsworth RE, Lum LG, Chang AE, Wicha MS, Li Q, Mace T, Makhijani N, Talbert E, Young G, Guttridge D, Conwell D, Lesinski GB, Gonzales RJMM, Huffman AP, Wang XK, Reshef R, MacKinnon A, Chen J, Gross M, Marguier G, Shwonek P, Sotirovska N, Steggerda S, Parlati F, Makkouk A, Bennett MK, Chen J, Emberley E, Gross M, Huang T, Li W, MacKinnon A, Marguier G, Neou S, Pan A, Zhang J, Zhang W, Parlati F, Marshall N, Marron TU, Agudo J, Brown B, Brody J, McQuinn C, Mace T, Farren M, Komar H, Shakya R, Young G, Ludwug T, Lesinski GB, Morillon YM, Hammond SA, Schlom J, Greiner JW, Nath PR, Schwartz AL, Maric D, Roberts DD, Obermajer N, Bartlett D, Kalinski P, Naing A, Papadopoulos KP, Autio KA, Wong DJ, Patel M, Falchook G, Pant S, Ott PA, Whiteside M, Patnaik A, Mumm J, Janku F, Chan I, Bauer T, Colen R, VanVlasselaer P, Brown GL, Tannir NM, Oft M, Infante J, Lipson E, Gopal A, Neelapu SS, Armand P, Spurgeon S, Leonard JP, Hodi FS, Sanborn RE, Melero I, Gajewski TF, Maurer M, Perna S, Gutierrez AA, Clynes R, Mitra P, Suryawanshi S, Gladstone D, Callahan MK, Crooks J, Brown S, Gauthier A, de Boisferon MH, MacDonald A, Brunet LR, Rothwell WT, Bell P, Wilson JM, Sato-Kaneko F, Yao S, Zhang SS, Carson DA, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Hayashi T, Cohen EEW, Schaer D, Li Y, Dobkin J, Amatulli M, Hall G, Doman T, Manro J, Dorsey FC, Sams L, Holmgaard R, Persaud K, Ludwig D, Surguladze D, Kauh JS, Novosiadly R, Kalos M, Driscoll K, Pandha H, Ralph C, Harrington K, Curti B, Sanborn RE, Akerley W, Gupta S, Melcher A, Mansfield D, Kaufman DR, Schmidt E, Grose M, Davies B, Karpathy R, Shafren D, Shamalov K, Cohen C, Sharma N, Allison J, Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A, Slomovitz BM, Moore KM, Youssoufian H, Posner M, Tewary P, Brooks AD, Xu YM, Wijeratne K, Gunatilaka LAA, Sayers TJ, Vasilakos JP, Alston T, Dovedi S, Elvecrog J, Grigsby I, Herbst R, Johnson K, Moeckly C, Mullins S, Siebenaler K, SternJohn J, Tilahun A, Tomai MA, Vogel K, Wilkinson RW, Vietsch EE, Wellstein A, Wythes M, Crosignani S, Tumang J, Alekar S, Bingham P, Cauwenberghs S, Chaplin J, Dalvie D, Denies S, De Maeseneire C, Feng J, Frederix K, Greasley S, Guo J, Hardwick J, Kaiser S, Jessen K, Kindt E, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Murray B, Pirson R, Preillon J, Rabolli V, Ray C, Ryan K, Scales S, Srirangam J, Solowiej J, Stewart A, Streiner N, Torti V, Tsaparikos K, Zheng X, Driessens G, Gomes B, Kraus M, Xu C, Zhang Y, Kradjian G, Qin G, Qi J, Xu X, Marelli B, Yu H, Guzman W, Tighe R, Salazar R, Lo KM, English J, Radvanyi L, Lan Y, Zappasodi R, Budhu S, Hellmann MD, Postow M, Senbabaoglu Y, Gasmi B, Zhong H, Li Y, Liu C, Hirschhorhn-Cymerman D, Wolchok JD, Merghoub T, Zha Y, Malnassy G, Fulton N, Park JH, Stock W, Nakamura Y, Gajewski TF, Liu H, Ju X, Kosoff R, Ramos K, Coder B, Petit R, Princiotta M, Perry K, Zou J, Arina A, Fernandez C, Zheng W, Beckett MA, Mauceri HJ, Fu YX, Weichselbaum RR, DeBenedette M, Lewis W, Gamble A, Nicolette C, Han Y, Wu Y, Yang C, Huang J, Wu D, Li J, Liang X, Zhou X, Hou J, Hassan R, Jahan T, Antonia SJ, Kindler HL, Alley EW, Honarmand S, Liu W, Leong ML, Whiting CC, Nair N, Enstrom A, Lemmens EE, Tsujikawa T, Kumar S, Coussens LM, Murphy AL, Brockstedt DG, Koch SD, Sebastian M, Weiss C, Früh M, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geissler M, Griesinger F, Kollmeier J, Papachristofilou A, Doener F, Fotin-Mleczek M, Hipp M, Hong HS, Kallen KJ, Klinkhardt U, Stosnach C, Scheel B, Schroeder A, Seibel T, Gnad-Vogt U, Zippelius A, Park HR, Ahn YO, Kim TM, Kim S, Kim S, Lee YS, Keam B, Kim DW, Heo DS, Pilon-Thomas S, Weber A, Morse J, Kodumudi K, Liu H, Mullinax J, Sarnaik AA, Pike L, Bang A, Ott PA, Balboni T, Taylor A, Spektor A, Wilhite T, Krishnan M, Cagney D, Alexander B, Aizer A, Buchbinder E, Awad M, Ghandi L, Hodi FS, Schoenfeld J, Schwartz AL, Nath PR, Lessey-Morillon E, Ridnour L, Roberts DD, Segal NH, Sharma M, Le DT, Ott PA, Ferris RL, Zelenetz AD, Neelapu SS, Levy R, Lossos IS, Jacobson C, Ramchandren R, Godwin J, Colevas AD, Meier R, Krishnan S, Gu X, Neely J, Suryawanshi S, Timmerman J, Vanpouille-Box CI, Formenti SC, Demaria S, Wennerberg E, Mediero A, Cronstein BN, Formenti SC, Demaria S, Gustafson MP, DiCostanzo A, Wheatley C, Kim CH, Bornschlegl S, Gastineau DA, Johnson BD, Dietz AB, MacDonald C, Bucsek M, Qiao G, Hylander B, Repasky E, Turbitt WJ, Xu Y, Mastro A, Rogers CJ, Withers S, Wang Z, Khuat LT, Dunai C, Blazar BR, Longo D, Rebhun R, Grossenbacher SK, Monjazeb A, Murphy WJ, Rowlinson S, Agnello G, Alters S, Lowe D, Scharping N, Menk AV, Whetstone R, Zeng X, Delgoffe GM, Santos PM, Menk AV, Shi J, Delgoffe GM, Butterfield LH, Whetstone R, Menk AV, Scharping N, Delgoffe G, Nagasaka M, Sukari A, Byrne-Steele M, Pan W, Hou X, Brown B, Eisenhower M, Han J, Collins N, Manguso R, Pope H, Shrestha Y, Boehm J, Haining WN, Cron KR, Sivan A, Aquino-Michaels K, Gajewski TF, Orecchioni M, Bedognetti D, Hendrickx W, Fuoco C, Spada F, Sgarrella F, Cesareni G, Marincola F, Kostarelos K, Bianco A, Delogu L, Hendrickx W, Roelands J, Boughorbel S, Decock J, Presnell S, Wang E, Marincola FM, Kuppen P, Ceccarelli M, Rinchai D, Chaussabel D, Miller L, Bedognetti D, Nguyen A, Sanborn JZ, Vaske C, Rabizadeh S, Niazi K, Benz S, Patel S, Restifo N, White J, Angiuoli S, Sausen M, Jones S, Sevdali M, Simmons J, Velculescu V, Diaz L, Zhang T, Sims JS, Barton SM, Gartrell R, Kadenhe-Chiweshe A, Dela Cruz F, Turk AT, Lu Y, Mazzeo CF, Kung AL, Bruce JN, Saenger YM, Yamashiro DJ, Connolly EP, Baird J, Crittenden M, Friedman D, Xiao H, Leidner R, Bell B, Young K, Gough M, Bian Z, Kidder K, Liu Y, Curran E, Chen X, Corrales LP, Kline J, Dunai C, Aguilar EG, Khuat LT, Murphy WJ, Guerriero J, Sotayo A, Ponichtera H, Pourzia A, Schad S, Carrasco R, Lazo S, Bronson R, Letai A, Kornbluth RS, Gupta S, Termini J, Guirado E, Stone GW, Meyer C, Helming L, Tumang J, Wilson N, Hofmeister R, Radvanyi L, Neubert NJ, Tillé L, Barras D, Soneson C, Baumgaertner P, Rimoldi D, Gfeller D, Delorenzi M, Fuertes Marraco SA, Speiser DE, Abraham TS, Xiang B, Magee MS, Waldman SA, Snook AE, Blogowski W, Zuba-Surma E, Budkowska M, Salata D, Dolegowska B, Starzynska T, Chan L, Somanchi S, McCulley K, Lee D, Buettner N, Shi F, Myers PT, Curbishley S, Penny SA, Steadman L, Millar D, Speers E, Ruth N, Wong G, Thimme R, Adams D, Cobbold M, Thomas R, Hendrickx W, Al-Muftah M, Decock J, Wong MKK, Morse M, McDermott DF, Clark JI, Kaufman HL, Daniels GA, Hua H, Rao T, Dutcher JP, Kang K, Saunthararajah Y, Velcheti V, Kumar V, Anwar F, Verma A, Chheda Z, Kohanbash G, Sidney J, Okada K, Shrivastav S, Carrera DA, Liu S, Jahan N, Mueller S, Pollack IF, Carcaboso AM, Sette A, Hou Y, Okada H, Field JJ, Zeng W, Shih VFS, Law CL, Senter PD, Gardai SJ, Okeley NM, Penny SA, Abelin JG, Saeed AZ, Malaker SA, Myers PT, Shabanowitz J, Ward ST, Hunt DF, Cobbold M, Profusek P, Wood L, Shepard D, Grivas P, Kapp K, Volz B, Oswald D, Wittig B, Schmidt M, Sefrin JP, Hillringhaus L, Lifke V, Lifke A, Skaletskaya A, Ponte J, Chittenden T, Setiady Y, Valsesia-Wittmann S, Sivado E, Thomas V, El Alaoui M, Papot S, Dumontet C, Dyson M, McCafferty J, El Alaoui S, Verma A, Kumar V, Bommareddy PK, Kaufman HL, Zloza A, Kohlhapp F, Silk AW, Jhawar S, Paneque T, Bommareddy PK, Kohlhapp F, Newman J, Beltran P, Zloza A, Kaufman HL, Cao F, Hong BX, Rodriguez-Cruz T, Song XT, Gottschalk S, Calderon H, Illingworth S, Brown A, Fisher K, Seymour L, Champion B, Eriksson E, Wenthe J, Hellström AC, Paul-Wetterberg G, Loskog A, Eriksson E, Milenova I, Wenthe J, Ståhle M, Jarblad-Leja J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A, Eriksson E, Milenova I, Moreno R. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. J Immunother Cancer 2016. [PMCID: PMC5123381 DOI: 10.1186/s40425-016-0173-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
22
|
Gutierrez M, Giaccone G, Liu S, Rajan A, Guha U, Halfdanarson T, Curtis K, Kunz P, Gabrail N, Hinson J, Orlemans E. Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Kelly KR, Gabrail N, Weitman S, Sarantopoulos J, Olszanski AJ, Edenfield W, Venitz J, Reddy G, Yang A, Hasal SJ, Lockhart AC. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemother Pharmacol 2016; 78:929-939. [PMID: 27638045 DOI: 10.1007/s00280-016-3142-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 08/23/2016] [Indexed: 12/01/2022]
Abstract
PURPOSE Pralatrexate is a folate analogue indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. It has not been formally tested in patients with renal impairment. This study evaluated the pharmacokinetic (PK) profile of pralatrexate in patients with renal impairment and with relapsed/refractory advanced solid tumors and lymphoma. METHODS This was an open-label, nonrandomized, phase 1 study. Eligible patients received pralatrexate administered as an IV push over 3-5 min once weekly for 6 weeks in 7-week cycles until progressive disease or intolerable toxicity. Four cohorts of 6 patients were planned for a total of 24 patients. Patients with normal renal function (Cohort A), mild (Cohort B), and moderate renal impairment (Cohort C) received 30 mg/m2 pralatrexate once weekly for 6 weeks in 7-week cycles, and patients with severe renal impairment (Cohort D) were to be administered 20 mg/m2 once weekly for 6 weeks. Plasma and urine samples were collected at pre-specified time points to determine the PK profile of pralatrexate in each treatment cohort. Patients were followed for safety and tolerability. RESULTS A total of 29 patients were enrolled and 27 patients (14 male) received at least 1 dose of pralatrexate. Because of a qualifying toxicity in Cohort C, the starting dose for Cohort D was reduced to 15 mg/m2. Chronic renal impairment led to a decrease in renal clearance of the pralatrexate diastereomers, PDX-10a and PDX-10b, but systemic exposure to these diastereomers was not dramatically affected by renal impairment. Pralatrexate exposure in Cohort D (15 mg/m2) was similar to the exposure in other cohorts (30 mg/m2). No apparent difference in toxicity between the four treatment cohorts was observed, except for an increase in cytopenias in patients with severe renal impairment. CONCLUSION Pralatrexate exposure, at a dose of 30 mg/m2, in patients with mild or moderate renal impairment was similar to the exposure in patients with normal renal function. For patients with severe renal impairment only, a pralatrexate dose of 15 mg/m2 is recommended.
Collapse
Affiliation(s)
- Kevin R Kelly
- Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, 1441 Eastlake Ave, NOR 3465, MC 9172, Los Angeles, CA, 90033, USA.
| | - Nashat Gabrail
- Gabrail Cancer Center Research, 4875 Higbee Ave. NW, Canton, OH, 44718, USA
| | - Steven Weitman
- UT Health Science Center, Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, TX, 78229, USA
| | - John Sarantopoulos
- UT Health Science Center, Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, TX, 78229, USA
| | | | - William Edenfield
- Greenville Hospital Systems Institute for Translational Oncology Research, 900 West Faris Rd CTC, 3rd Floor, CRU, Greenville, SC, 29605, USA
| | - Jurgen Venitz
- Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, 410 N 12th Street, P.O. Box 980533, Richmond, VA, 23298-0533, USA
| | - Guru Reddy
- Spectrum Pharmaceuticals, Inc., 157 Technology Dr., Irvine, CA, 92618, USA
| | - Allen Yang
- Spectrum Pharmaceuticals, Inc., 157 Technology Dr., Irvine, CA, 92618, USA
| | - Steven J Hasal
- Spectrum Pharmaceuticals, Inc., 157 Technology Dr., Irvine, CA, 92618, USA
| | - A Craig Lockhart
- Washington University School of Medicine, 660 Euclid Avenue, St. Louis, MO, 63110, USA
| |
Collapse
|
24
|
Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer 2015; 24:1517-25. [PMID: 26370220 PMCID: PMC4766217 DOI: 10.1007/s00520-015-2929-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Accepted: 08/31/2015] [Indexed: 02/05/2023]
Abstract
Purpose Sotatercept may represent a novel approach to the treatment of chemotherapy-induced anemia (CIA). We report the results from two phase 2 randomized studies examining the use of sotatercept for the treatment of CIA in patients with metastatic cancer. Methods In study A011-08, patients with metastatic breast cancer were randomized to 2:2:2:1 to receive sotatercept 0.1, 0.3, or 0.5 mg/kg, or placebo, respectively, every 28 days. In study ACE-011-NSCL-001, patients with solid tumors treated with platinum-based chemotherapy received sotatercept 15 or 30 mg every 42 days. The primary endpoint for both studies was hematopoietic response, defined as a hemoglobin (Hb) increase of ≥1 g/dL from baseline. Results Both studies were terminated early due to slow patient accrual. Among patients treated with sotatercept in the A011-08 and ACE-011-NSCL-001 studies, more patients achieved a mean Hb increase of ≥1 g/dL in the combined sotatercept 0.3 mg/kg and 15 mg (66.7 %) group and sotatercept 0.5 mg/kg and 30 mg (38.9 %) group versus the sotatercept 0.1 mg/kg (0 %) group. No patients achieved a mean Hb increase of ≥1 g/dL in the placebo group. The incidence of treatment-related adverse events (AEs) was low in both studies, and treatment discontinuations due to AEs were uncommon. Conclusions Although both studies were terminated early, these results indicate that sotatercept is active and has an acceptable safety profile in the treatment of CIA.
Collapse
Affiliation(s)
- Haralambos Raftopoulos
- Monter Cancer Center, Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Road, Lake Success, NY, 11042, USA.
| | | | - Paul J Hesketh
- Lahey Hospital & Medical Center, Tufts University School of Medicine, Burlington, MA, USA
| | | | | | | | | | | | - Ding Wang
- Josephine Ford Cancer Institute, Detroit, MI, USA
| | | | | | - Jun Zou
- Celgene Corporation, Summit, NJ, USA
| | | |
Collapse
|
25
|
Gabrail N, Ghamande S, Silverman M, Smith C, Ho H, Huang C, Hsueh S, Lin C. 330 First-in-man study of gemcitabine hydrochloride oral formulation (D07001-F4) in patients with malignant tumors. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30194-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Prada C, Shain K, Voorhees P, Gabrail N, Abidi M, Zonder J, Boccia R, Richardson P, Neuman L, Wong H, Dixon S, Hari P. Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study. Clinical Lymphoma Myeloma and Leukemia 2015. [DOI: 10.1016/j.clml.2015.07.569] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. J Clin Oncol 2015; 33:3921-9. [PMID: 26056177 DOI: 10.1200/jco.2014.58.7618] [Citation(s) in RCA: 119] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
PURPOSE The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bortezomib-based regimens in transplantation-ineligible patients with myeloma. PATIENTS AND METHODS Patients (N = 502) were randomly assigned 1:1:1 to 24 weeks (eight 21-day cycles) of induction with bortezomib-dexamethasone (VD; n = 168; intravenous bortezomib 1.3 mg/m(2), days 1, 4, 8, and 11 plus oral dexamethasone 20 mg, days 1, 2, 4, 5, 8, 9, 11, and 12 [cycles 1 to 4], or 1, 2, 4, and 5 [cycles 5 to 8]), bortezomib-thalidomide-dexamethasone (VTD; n = 167; bortezomib and dexamethasone as before plus oral thalidomide 100 mg, days 1 to 21), or bortezomib-melphalan-prednisone (VMP; n = 167; bortezomib as before plus oral melphalan 9 mg/m(2) and oral prednisone 60 mg/m(2), days 1 to 4, every other cycle), followed by 25 weeks (five 35-day cycles) of bortezomib maintenance (1.6 mg/m(2), days 1, 8, 15, and 22). The primary end point was progression-free survival. RESULTS After 42.7 months' median follow-up, median progression-free survival with VD, VTD, and VMP was 14.7, 15.4, and 17.3 months, respectively; median overall survival was 49.8, 51.5, and 53.1 months, with no significant differences among treatments for either end point (global P = .46 and P = .79, respectively, Wald test). Overall response rates were 73% (VD), 80% (VTD), and 70% (VMP). Adverse events were more common with VTD than VD or VMP. Bortezomib maintenance was feasible without producing cumulative toxicity. CONCLUSION Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.
Collapse
Affiliation(s)
- Ruben Niesvizky
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL.
| | - Ian W Flinn
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Robert Rifkin
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Nashat Gabrail
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Veena Charu
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Billy Clowney
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - James Essell
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Yousuf Gaffar
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Thomas Warr
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Rachel Neuwirth
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Yanyan Zhu
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Jennifer Elliott
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Dixie-Lee Esseltine
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - Liviu Niculescu
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| | - James Reeves
- Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL
| |
Collapse
|
28
|
Gabrail N, Yanagihara R, Spaczyński M, Cooper W, O’Boyle E, Smith C, Boccia R. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Manag Res 2015; 7:83-92. [PMID: 25834466 PMCID: PMC4370683 DOI: 10.2147/cmar.s72626] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy-induced nausea and vomiting (CINV) despite use of antiemetics. APF530 is a sustained-release subcutaneous (SC) formulation of granisetron for preventing CINV. APF530 pharmacokinetics, safety, and efficacy were studied in two open-label, single-dose Phase II trials (C2005-01 and C2007-01, respectively) in patients receiving moderately emetogenic chemotherapy or highly emetogenic chemotherapy. METHODS In C2005-01, 45 patients received APF530 250, 500, or 750 mg SC (granisetron 5, 10, or 15 mg, respectively). In C2007-01, 35 patients were randomized to APF530 250 or 500 mg SC. Injections were given 30 to 60 minutes before single-day moderately emetogenic chemotherapy or highly emetogenic chemotherapy. Plasma granisetron was measured from predose to 168 hours after study drug administration. Safety and efficacy were also evaluated. RESULTS APF530 pharmacokinetics were dose proportional, with slow absorption and elimination of granisetron after a single SC dose. Median time to maximum plasma concentration and half-life were similar for APF530 250 and 500 mg in both trials, with no differences between the groups receiving moderately and highly emetogenic chemotherapy. Exposure to granisetron was maintained at a therapeutic level over the delayed-onset phase, at least 168 hours. Adverse events in both trials were as expected for granisetron; injection site reactions (eg, erythema and induration) were predominantly mild and seen in ≤20% of patients. Complete responses (no emesis, with no rescue medication) were obtained in the acute, delayed, and overall phases in ≥80% and ≥75% of patients in both trials with the 250 and 500 mg doses, respectively. CONCLUSION After a single injection of APF530, there were dose-proportional pharmacokinetics and sustained concentrations of granisetron over 168 hours. The 250 and 500 mg doses were well tolerated and maintained therapeutic granisetron levels for ≥5 days.
Collapse
Affiliation(s)
| | | | - Marek Spaczyński
- Department of Gynecology, Obstetrics and Gynecologic Oncology, University of Medical Sciences, Poznan, Poland
| | | | | | | | - Ralph Boccia
- Center for Cancer and Blood Disorders, Bethesda, MD, USA
| |
Collapse
|
29
|
Wydra D, Ghamande S, Gabrail N, Nowara E, Bidzinski M, Depasquale S, Clark R, Penson R. Precedent Subset Analysis: Safety and Disease Control with Vintafolide Monotherapy Following Discontinuation of Pegylated Liposomal Doxorubicin (Pld). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Harrop R, Chu F, Gabrail N, Srinivas S, Blount D, Ferrari A. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunol Immunother 2013; 62:1511-20. [PMID: 23877659 PMCID: PMC11029002 DOI: 10.1007/s00262-013-1457-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2013] [Accepted: 07/09/2013] [Indexed: 11/25/2022]
Abstract
The attenuated vaccinia virus, modified vaccinia Ankara, has been engineered to deliver the tumor antigen 5T4 (TroVax®). Here, we report results from a randomized open-label phase II trial in castration-resistant prostate cancer patients in which TroVax was administered in combination with docetaxel and compared against docetaxel alone. The aim was to recruit 80 patients (40 per arm), but the study was terminated early due to recruitment challenges. Therefore, this paper reports the comparative safety and immunological and clinical efficacy in 25 patients, 12 of whom were treated with TroVax plus docetaxel and 13 with docetaxel alone. 5T4-specific immune responses were monitored throughout the study. Clinical responses were assessed by measuring changes in tumor burden by CT and bone scan and by quantifying PSA concentrations. TroVax was well tolerated in all patients. Of 10 immunologically evaluable patients, 6 mounted 5T4-specific antibody responses. Patients treated with TroVax plus docetaxel showed a greater median progression-free survival of 9.67 months compared with 5.10 months for patients on the docetaxel alone arm (P = 0.097; HR = 0.31; 95% CI 0.08-1.24). Importantly, a pre-treatment biomarker previously demonstrated to predict 5T4 immune response and treatment benefit showed a strong association with 5T4 antibody response and a statistically significant association with progression-free survival in patients treated with TroVax plus docetaxel, but not docetaxel alone.
Collapse
Affiliation(s)
- Richard Harrop
- Oxford BioMedica (UK) Ltd., The Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK.
| | | | | | | | | | | |
Collapse
|
31
|
Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol 2013; 31:2548-53. [PMID: 23733767 PMCID: PMC4878053 DOI: 10.1200/jco.2012.44.6823] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
PURPOSE This open-label, randomized phase II trial assessed efficacy and tolerability of two low-dose regimens of subcutaneous (SC) decitabine in patients with low- or intermediate-1-risk myelodysplastic syndrome (MDS). PATIENTS AND METHODS Patients received decitabine 20 mg/m(2) SC per day for 3 consecutive days on days 1, 2, and 3 every 28 days (schedule A) or 20 mg/m(2) SC per day once every 7 days on days 1, 8, and 15 every 28 days (schedule B) for up to 1 year. Primary efficacy end point was overall improvement rate (OIR: complete remission [CR], partial remission [PR], marrow CR [mCR], or hematologic improvement [HI]). Secondary end points were HI, transfusion independence, cytogenetic response, overall survival (OS), and time to acute myeloid leukemia or death. RESULTS Efficacy and safety populations were identical: schedule A, n = 43; schedule B, n = 22. Median time from MDS diagnosis to treatment was 3.6 months; 89% had de novo MDS. The trial was terminated early on achievement of protocol-defined OIR superiority of schedule A over schedule B; OIR was 23% for schedule A (seven CRs, three HIs) and 23% for schedule B (one mCR, one PR, three HIs). No differences were observed in secondary end points. Median OS was not reached; approximately 70% of patients were alive at 500 days. Patients in schedule A (67%) and schedule B (59%) were RBC/platelet independent on study. The most frequent drug-related adverse events overall were neutropenia (28% v 36%), anemia (23% v 18%), and thrombocytopenia (16% v 32%). CONCLUSION In this phase II study, low-dose decitabine showed promising results in patients with low- or intermediate-1-risk MDS.
Collapse
Affiliation(s)
- Guillermo Garcia-Manero
- The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Liu F, Talpaz M, Pardanani A, Jamieson C, Gabrail N, Tefferi A, Lei T, Greco R, Adrian F, Daskalakis N, Lebedinsky C, Cohen P, Bergstrom D. Abstract LB-294: Determination of JAK2V617F allele burden in a phase II study of patients with myelofibrosis treated with SAR302503 using a sensitive and robust allele-specific qPCR assay. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-lb-294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Janus kinase-2 (JAK2)/STAT pathway activation is commonly observed in myeloproliferative neoplasms and plays an important role in disease development and progression. The V617F activating mutation in the JAK2 pseudokinase domain is found in 95% of patients with polycythemia vera (PV) and in 50-70% of patients with primary myelofibrosis (MF) or essential thrombocythemia (ET). Studies have shown the clinical efficacy of JAK2 inhibitors in treating MF in terms of a reduction in splenomegaly and relief of constitutional symptoms. A reduction in the JAK2V617F allele burden after treatment with a JAK2-targeted agent could be a surrogate for a disease-modifying effect of this therapy. To demonstrate this, a robust method that can accurately measure the JAK2V617F allele burden is required. Here, we report the development of a sensitive quantitative PCR (qPCR) assay to determine the JAK2V617F allele burden in patients treated with SAR302503, the validation of the assay in a Phase 0 clinical study and implementation in a phase II study using samples from patients with MF. The assay demonstrated robust performance, with high sensitivity (LLOD=0.05% and LLOQ=0.5%) and accuracy. A phase 0 study in MF, PV, and ET patients showed that (1) there was minimal intra-subject sampling variability in JAK2V617F allele burden, and (2) whole-blood samples are stable for at least 48 hours at ambient conditions for DNA preparation without a significant impact on JAK2V617F allele burden measurement.Of the 31 patients with intermediate-2 or high-risk MF enrolled in a phase II clinical study (NCT01420770), baseline samples were available for 29 patients and of these, 26 were JAK2V617F-positive using this assay. Of the 19/26 patients for whom samples were available at all 3 time points, the median allele burden was 93% at baseline, 87% at the end of Cycle 3, and 78% at the end of Cycle 6. Among the 24 patients who were JAK2V617F-positive and for whom spleen measurements were available at the end of Cycle 6, a total of 15 (63%) had a spleen response (≥ 35% reduction in spleen volume by MRI versus baseline). In contrast, two JAK2V617F-negative patients did not have a spleen response. Patients with baseline allele burden levels of 0 to <25%, 25% to 75%, and ≥75% showed spleen response rates of 50%, 44%, and 69%, respectively, at the end of Cycle 6. JAK2V617F allele burden will continue to be assessed every 3 cycles. Longer follow up is needed to determine the clinical effect of allele burden reduction.
Citation Format: Feng Liu, Moshe Talpaz, Animesh Pardanani, Catriona Jamieson, Nashat Gabrail, Ayalew Tefferi, Tianlei Lei, Rita Greco, Francisco Adrian, Nikki Daskalakis, Claudia Lebedinsky, Pamela Cohen, Donald Bergstrom. Determination of JAK2V617F allele burden in a phase II study of patients with myelofibrosis treated with SAR302503 using a sensitive and robust allele-specific qPCR assay. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-294. doi:10.1158/1538-7445.AM2013-LB-294
Collapse
|
33
|
Gulley J, Gabrail N, Vogelzang N, Rainwater L, Blitz B, Hodge G, Lipsitz D, Shore N, Sieber P, Stewart S, Crabb S, Bandman O, Delcayre A, Goessl C, Laus R, Schlom J, Kantoff P. 970 PROSPECT: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 EFFICACY TRIAL OF PROSTVAC-VF IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. J Urol 2013. [DOI: 10.1016/j.juro.2013.02.551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Eng C, Alberto B, Gabrail N, Lopez T, Zahir H, von Roemeling R, Bendell J. PD-0018 Phase I/II Study of Tivantinib (ARQ 197) Irinotecan, and Cetuximab in Patients with Kras Wildtype, Previously Treated, Metastatic Colorectal Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(19)66512-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
35
|
Torres L, Lynch L, Revnic J, Ramos M, Reale C, Gabrail N. 3011 POSTER 18-Month Safety Analysis of Fentanyl Pectin Nasal Spray (FPNS) in Patients With Breakthrough Pain in Cancer (BTPC). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71084-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
36
|
Bessudo A, Bendell JC, Gabrail N, Kopp MV, Mueller L, Hart LL, Vladimirov VI, Pande AU, Gorbatchevsky I, Eng C. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3582] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Niesvizky R, Flinn IW, Rifkin RM, Gabrail N, Charu V, Gaffar Y, Neuwirth R, Corzo D, Reeves J. Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Garon E, Neidhart J, Neidhart J, Kabbinavar F, Gabrail N, de Oliveira MR, Lu S, Balkissoon J. 467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72174-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
39
|
Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, Acharya M, Chan K, Cohen N, Dudov A. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009; 48:199-209. [PMID: 19385713 DOI: 10.2165/00003088-200948030-00006] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND AND OBJECTIVE Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19. Omeprazole, a proton-pump inhibitor, is primarily metabolized by and demonstrates high affinity for CYP2C19. This study investigated whether coadministration of omeprazole affected the pharmacokinetics, pharmacodynamics and safety profile of bortezomib in patients with advanced cancer. The variability of bortezomib pharmacokinetics with CYP enzyme polymorphism was also investigated. PATIENTS AND METHODS This open-label, crossover, pharmacokinetic drug-drug interaction study was conducted at seven institutions in the US and Europe between January 2005 and August 2006. Patients who had advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma, were aged >/=18 years, weighed >/=50 kg and had a life expectancy of >/=3 months were eligible. Patients received bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 for two 21-day cycles, plus omeprazole 40 mg in the morning of days 6-10 and in the evening of day 8 in either cycle 1 (sequence 1) or cycle 2 (sequence 2). On day 21 of cycle 2, patients benefiting from therapy could continue to receive bortezomib for six additional cycles. Blood samples for pharmacokinetic/pharmacodynamic evaluation were collected prior to and at various timepoints after bortezomib administration on day 8 of cycles 1 and 2. Blood samples for pharmacogenomics were also collected. Pharmacokinetic parameters were calculated by noncompartmental analysis of plasma concentration-time data for bortezomib administration on day 8 of cycles 1 and 2, using WinNonlin version 4.0.1.a software. The pharmacodynamic profile was assessed using a whole-blood 20S proteasome inhibition assay. RESULTS Twenty-seven patients (median age 64 years) were enrolled, 12 in sequence 1 and 15 in sequence 2, including eight and nine pharmacokinetic-evaluable patients, respectively. Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL). The pharmacodynamic parameters were also similar (maximum effect 85.8% vs 93.7%; area under the percent inhibition-time curve over 72 hours 4052 vs 3910 % x h); the differences were not statistically significant. Pharmacogenomic analysis revealed no meaningful relationships between CYP enzyme polymorphisms and pharmacokinetic/pharmacodynamic parameters. Toxicities were generally similar between patients in sequence 1 and sequence 2, and between cycle 1 and cycle 2 in both treatment sequences. Among 26 evaluable patients, 13 (50%) were assessed as benefiting from bortezomib at the end of cycle 2 and continued to receive treatment. CONCLUSION No impact on the pharmacokinetics, pharmacodynamics and safety profile of bortezomib was seen with coadministration of omeprazole. Concomitant administration of bortezomib and omeprazole is unlikely to cause clinically significant drug-drug interactions and is unlikely to have an impact on the efficacy or safety of bortezomib.
Collapse
Affiliation(s)
- David I Quinn
- University of Southern California, Los Angeles, California, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Grous JJ, Riegel E, Gabrail N, Charu V, Arevalo-Araujo R, Yanagihara R, Nguyen A, Robertson P, Cooper B, O'Boyle E, Barr J. Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9627] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9627 Background: APF530 is a polymeric formulation of granisetron providing sustained drug release over 5 days. Two doses (5 and 10 mg) of subcutaneous APF530 were evaluated in comparison to 0.25 mg intravenous palonosetron. Efficacy was evaluated in acute (0–24 hrs) and delayed (24–120 hrs) CINV among patients receiving moderate (MEC) or highly (HEC) emetogenic chemotherapy. Methods: Randomized, blinded patients (n=1,395) were stratified into MEC or HEC according to Hesketh et al 1999, and assigned to receive either dose of APF530 or palonosetron. Dexamethasone use was standardized based on the emetogenic strata. Patient diaries recorded emetic episodes, nausea and rescue medications over a 5-day period. Primary endpoint was Complete Response (CR), defined as no emetic episodes and no rescue medication. Non-inferiority to palonosetron was declared if the lower bound of the CI for the difference was above -15%. Results: APF530 was well tolerated. Adverse events were consistent with those previously reported for granisetron. For APF530 Tmax was observed about 24 hrs with sustained levels over 120 hrs. For MEC acute phase CR rates of 74.8% (n=214), 76.9% (n=212) and 75.0% (n=208) were observed for 5 mg, 10 mg APF530 and palonosetron, respectively. Delayed phase CR rates of 51.4%, 59.0% and 57.7% were observed for 5 mg, 10 mg APF530 and palonosetron, respectively. For HEC acute phase CR rates of 77.7% (n=229), 81.3% (n=240) and 80.7% (n=238) were observed for 5 mg, 10 mg APF530 and palonosetron, respectively. Delayed phase CR rates of 64.6%, 68.3% and 66.4% were observed for 5 mg, 10 mg APF530 and palonosetron, respectively. Efficacy was maintained with APF530 over multiple cycles (up to 4). Conclusions: Both doses of APF530 were non-inferior to palonosetron with respect to CR during the acute phase following MEC and HEC. Only the higher dose of APF530 (10 mg granisetron) was non-inferior to palonosetron during the delayed phase of MEC. Both doses of APF530 were comparable to the CR rates of palonosetron during the delayed phase of HEC. [Table: see text]
Collapse
Affiliation(s)
- J. J. Grous
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - E. Riegel
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - N. Gabrail
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - V. Charu
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - R. Arevalo-Araujo
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - R. Yanagihara
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - A. Nguyen
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - P. Robertson
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - B. Cooper
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - E. O'Boyle
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| | - J. Barr
- Beardsworth Consulting Group, Inc., Flemington, NJ; Gabrail Cancer Center, Canton, OH; Pacific Cancer Medical Center, Anaheim, CA; Pasco Pinellas Cancer Center, New Port Richey, FL; Ronald Yanagihara Cancer Center, Gilroy, CA; AN Cancer Center, Fountain Valley, CA; Western Washington Oncology, Lacey, WA; AP Pharma, Redwood City, CA
| |
Collapse
|
41
|
Bukowski RM, Stadler WM, Figlin RA, Knox JJ, Gabrail N, McDermott DF, Cupit L, Miller WH, Hainsworth JD, Ryan CW. Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5045] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Hurwitz H, Nelson B, O’Dwyer PJ, Chiorean EG, Gabrail N, Li Z, Laille E, Drouin M, Rothenberg ML, Chan E. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4625] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Batist G, Sawyer M, Gabrail N, Christiansen N, Marshall JL, Spigel DR, Louie A. A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4108] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14:2756-62. [PMID: 18451242 DOI: 10.1158/1078-0432.ccr-07-1372] [Citation(s) in RCA: 180] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways. A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies. EXPERIMENTAL DESIGN Eligible patients were assigned to one of five disease-specific, parallel cohorts and given 12.5 mg deforolimus as a 30-minute infusion once daily for 5 days every 2 weeks. A Simon two-stage design was used for each cohort. Safety, pharmacokinetics, pharmacodynamics, and antitumor response were assessed. RESULTS Fifty-five patients received deforolimus as follows: cohort 1 23 acute myelogenous leukemia, two myelodysplastic syndrome and one chronic myelogenous leukemia in nonlymphoid blast phase; cohort 2, one acute lymphocytic leukemia; cohort 3, nine agnogenic myeloid metaplasia; cohort 4, eight chronic lymphocytic leukemia; cohort 5, nine mantle cell lymphoma and two T-cell leukemia/lymphoma. Most patients were heavily pretreated. Of the 52 evaluable patients, partial responses were noted in five (10%), two of seven agnogenic myeloid metaplasia and three of nine mantle cell lymphoma. Hematologic improvement/stable disease was observed in 21 (40%). Common treatment-related adverse events, which were generally mild and reversible, were mouth sores, fatigue, nausea, and thrombocytopenia. Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus. CONCLUSIONS Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies, and antitumor activity was observed. Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies.
Collapse
Affiliation(s)
- David A Rizzieri
- Duke University Medical Center, Durham, North Carolina 27710, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Knox JJ, Figlin RA, Stadler WM, McDermott DF, Gabrail N, Miller WH, Hainsworth J, Ryan CW, Cupit L, Bukowski RM. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5011] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5011 Background: A prior phase III trial (TARGETs) demonstrated that sorafenib (SOR) doubled median progression-free survival versus placebo in previously treated clear cell renal cell cancer (RCC) patients (pts). The ARCCS trial made SOR available to a broader range of RCC pts through an expanded access program. Methods: This open-label, nonrandomized trial enrolled pts with advanced RCC not eligible for, or without access to, other SOR clinical trials; ECOG PS 0–2 with waivers granted for pts with ECOG PS 3–4; age =15 yrs; and adequate prior treatment of brain metastases. Major exclusion criteria included treatment <4 wks prior, life expectancy <2 mos, uncontrolled hypertension, and severe renal impairment requiring dialysis. Objectives were to analyze the safety and efficacy (response by RECIST) of 400 mg bid SOR in a community-based setting. Enrollment ceased on 12/20/05 when SOR became commercially available in the US, and those with no prior therapy or non-clear cell RCC continued in an extension protocol. Enrollment completed in Canada in 8/06. Results: A total of 2488 pts were valid for safety: 69% male with median age 63 yrs and most (83%) had prior nephrectomy; histologies included 78% clear-cell, 7% papillary, 1% chromophobe, and <1% collecting duct and oncocytoma. Median time from diagnosis for all pts was 1.4 yrs (range <1–34). Of those pts receiving prior therapy (n=1249), treatments included interferon alfa (54%), interleukin 2 (43%), bevacizumab (23%), thalidomide (12%), and sunitinib (2%). Grade 3 and 4 adverse events occurring in > 2% pts were hand- foot skin reaction 7.2%, fatigue 5.3%, hypertension 4.4%, rash/desquamation 4%, dehydration and dyspnea 2.7%, and diarrhea 2.5%. Efficacy assessment, mainly PFS, was limited by the short median time (14 wks) on study due to many pts enrolling during the last 2 months of the study. Of 1,850 pts evaluable for response, 17.5% had unconfirmed PR. One (0.1%), 67 (3.6%), 1479 (79.9%) and 303 (16.4%) had CR, PR, SD, and PD, respectively. Conclusions: ARCCS pts were representative of the broader range of RCC pts in the community including those excluded from previous SOR trials. Toxicity and response rates were similar to those reported previously, supporting the generalizability of the phase III trial data. [Table: see text]
Collapse
Affiliation(s)
- J. J. Knox
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - R. A. Figlin
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - W. M. Stadler
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - D. F. McDermott
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - N. Gabrail
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - W. H. Miller
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - J. Hainsworth
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - C. W. Ryan
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - L. Cupit
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| | - R. M. Bukowski
- Princess Margaret Hospital, Toronto, ON, Canada; City of Hope Comprehensive Cancer Center, Los Angeles, CA; University of Chicago Medical Center, Chicago, IL; Beth Israel Deaconess Medical Center, Boston, MA; Gabrail Cancer Center, Canton, OH; Jewish General Hospital, McGill University, Montreal, PQ, Canada; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Portland, OR; Bayer HealthCare, West Haven, CT; Cleveland Clinic Foundation, Cleveland, OH
| |
Collapse
|
46
|
Bellet RE, Ghazal H, Flam M, Drelichman A, Gabrail N, Woytowitz D, Loesch D, Niforos D, Mangione A, Anthony L. A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9109] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9109 Background: The effect of using IV iron sucrose in managing cancer chemotherapy-related anemia has not been previously reported. To investigate this issue, we conducted a randomized study of IV iron sucrose in patients (pts) with cancer chemotherapy-related anemia who completed 8 prior wks of ESA therapy. Methods: This prospective, multicenter, randomized, open label, Phase III clinical trial enrolled 375 pts with chemotherapy induced anemia (Hgb levels = 10.0 g/dL) and was conducted in 2 stages. During Stage I (8-wk duration), pts received treatment with fixed ESA doses (100-mcg of darbepoetin or 40,000 units epoetin wkly or 200 mcg of darbepoetin every other wk). Pts were classified as either ESA responders (= 1 g/dL increase in Hgb) or ESA non-responders with each group randomized (Stage 2) separately to receive either 12 wks of fixed doses of ESA plus up to 1,500 mg of iron sucrose (given in 3 divided doses of up to 500mg) or 12 wks of fixed doses of ESA alone. Laboratories (including iron indices and acute phase reactants), quality of life and adverse events were assessed at baseline and throughout. Results: Iron sucrose plus ESA compared to ESA alone resulted in greater mean maximum Hgb levels and greater number of pts who achieved Hgb increases = 2.0 and ≥ 3.0 g/dl in both prior ESA responders and non-responders. There was also a statistically significant improvement in fatigue and iron stores in the iron sucrose treated pts. Baseline iron status did not predict responsiveness to iron sucrose therapy. Three serious but non-life threatening iron sucrose related adverse events were observed including one case of significant, transient hypotension in a female weighing 50 kg. Conclusions: IV iron sucrose increased Hgb levels and iron stores significantly and is well tolerated in doses up to 500 mg increments in ESA treated patients with cancer chemotherapy- related anemia. IV iron sucrose should be considered in combination with erythropoietic therapy in anemic cancer patients receiving chemotherapy. [Table: see text]
Collapse
Affiliation(s)
- R. E. Bellet
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - H. Ghazal
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - M. Flam
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - A. Drelichman
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - N. Gabrail
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - D. Woytowitz
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - D. Loesch
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - D. Niforos
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - A. Mangione
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - L. Anthony
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | | |
Collapse
|
47
|
Santoro A, Voglova J, Gabrail N, Ciuleanu T, Liberati M, Hancock BW, Stromatt S, Caballero D. Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7578] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7578 Background: BBR 2778 is a novel aza-anthracenedione that shows structural similarities to the anthracyclines, demonstrates single agent activity in patients with NHL, and does not exhibit cardiotoxic effects in animal models. This phase III open-label study was designed to compare the efficacy and tolerability of combination rituximab and BBR 2778, with that of single agent rituximab, in patients (pts) with relapsed or refractory indolent NHL. Methods: Pts were randomly assigned to receive both rituximab and BBR 2778 (experimental arm), or rituximab alone (control arm). In the experimental arm, pts received 375 mg/m2 rituximab IV on days 1 and 8 of cycles 1 and 2 only, and 90 mg/m2 BBR 2778 IV on days 2 and 8 of cycle 1, and on days 1 and 8 of all subsequent cycles. Pts could receive six 21-day cycles of BBR 2778. In the control arm, pts received 375 mg/m2 rituximab IV on days 1, 8 and 15 of cycle 1 and day 1 of cycle 2 only. Disease response was assessed every other cycle according to International Workshop to Standardize Response Criteria for NHL. Toxicities were assessed throughout the study using NCI-CTC criteria. Study was closed early due to poor enrollment. Results: 38 pts (20 experimental, 18 control) were enrolled. Mean age was 66 and 59 years in the experimental and control arm, respectively. Most patients were males and most had ECOG performance status 0 or 1. Efficacy is summarized in the table. Response rate (75 vs 33%) and time to progression (13.2 vs 8.1 months) were better in the BBR 2778 arm. Only pts in the experimental arm had study drug related serious adverse events (2 febrile neutropenia, 1 pneumonia, 1 neutropenia) and adverse events resulting in withdrawal (6 vs 0). Conclusions: Combination of BBR 2778 and rituximab is superior to rituximab alone with regard to time to progression and overall response rate. BBR 2778 combined with rituximab appeared to be a generally well tolerated regimen in patients with relapsed/refractory indolent NHL. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- A. Santoro
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| | - J. Voglova
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| | - N. Gabrail
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| | - T. Ciuleanu
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| | - M. Liberati
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| | - B. W. Hancock
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| | - S. Stromatt
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| | - D. Caballero
- Istituto Clinico Humanitas, Rozzano, Italy; Internal Clinic Department of Clinical Haematology, Hradec Kralove, Czech Republic; Gabrail Cancer Center, Canton, OH; Oncology Insitute, Cluj-Napoca, Romania; Universita degli Studi di Perugia, Perugia, Italy; Weston Park Hospital, Sheffield, United Kingdom; Cell Therapeutics, Inc., Seattle, WA; Hospital Clinico Servicio de Hematologia, Salamanca, Spain
| |
Collapse
|
48
|
Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L. Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly. Clin Breast Cancer 2005; 6:446-54. [PMID: 16381629 DOI: 10.3816/cbc.2005.n.050] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Current chemotherapy regimens for breast cancer result in high incidences of anemia, which can be treated with erythropoietic agents. The relative efficacy of darbepoetin alfa and epoetin alfa was explored in this phase II, open-label, randomized, multicenter trial in anemic patients with breast cancer receiving chemotherapy. PATIENTS AND METHODS Patients were randomized at a 1:1 ratio to receive darbepoetin alfa 200 microg every 2 weeks (n = 72) or epoetin alfa 40,000 U weekly (n = 69) for < or = 16 weeks. Clinical and hematologic endpoints and validation of a novel patient satisfaction questionnaire for anemia treatment were evaluated for all patients randomized to receive > or = 1 dose of study drug. RESULTS Baseline characteristics were generally similar between treatment groups. Mean changes in hemoglobin (Hb) level from baseline were similar at 1.9 g/dL for darbepoetin alfa and 1.7 g/dL for epoetin alfa. Hematopoietic responses (> or = 2 g/dL increase in Hb level from baseline or Hb level > or = 12 g/dL) were also similar between groups (88% for darbepoetin alfa and 81% for epoetin alfa). The proportions of patients who received a transfusion during treatment were 6% (95% CI, 0-11%) for darbepoetin alfa and 16% (95% CI, 7%-25%) for epoetin alfa. Most patients (67 patients receiving darbepoetin alfa [93%]; 61 patients receiving epoetin alfa [90%]) exhibited a clinically meaningful target Hb level > or = 11 g/dL. No differences in safety were observed. CONCLUSION These results suggest that, in patients with breast cancer, darbepoetin alfa 200 microg every 2 weeks and epoetin alfa 40,000 U weekly result in comparable clinical outcomes for the treatment of chemotherapy-induced anemia.
Collapse
|
49
|
Rizvi N, Villalona-Calero M, Lynch T, Yee L, Gabrail N, Sandler A, Cropp G, Graham M, Palmer G. P-565 A Phase II study of KOS-862 (Epothilone D) as second-linetherapy in non-small cell lung cancer. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81058-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Yee L, Lynch T, Villalona-Calero M, Rizvi N, Gabrail N, Sandler A, Cropp G, Palmer G. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7127] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Yee
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| | - T. Lynch
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| | - M. Villalona-Calero
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| | - N. Rizvi
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| | - N. Gabrail
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| | - A. Sandler
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| | - G. Cropp
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| | - G. Palmer
- Northwest Medcl Specialties, Tacoma, WA; MA Gen Hosp, Boston, MA; Ohio State Univ, Columbus, OH; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Gabrail Cancer Ctr, Columbus, OH; Vanderbilt Univ Medcl Ctr, Nashville, TN; Kosan Biosciences, Hayward, CA
| |
Collapse
|